SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
SEC Accession No. 0001072613-18-000128
Filing Date
2018-02-12
Accepted
2018-02-12 16:17:16
Documents
1
Group Members
CLARUS VENTURES I MANAGEMENT, L.P.CLARUS VENTURES I, LLCDENNIS HENNERKURT WHEELERNICHOLAS GALAKATOSNICHOLAS SIMONROBERT LIPTAK

Document Format Files

Seq Description Document Type Size
1 CLARUS LIFESCIENCES I, L.P. OXFORD IMMUNOTEC GLOBAL PLC SCHEDULE 13GA - AMEND. # clarus-oxfordsch13g_18164.htm SC 13G/A 65497
  Complete submission text file 0001072613-18-000128.txt   67292
Mailing Address 101 MAIN STREET SUITE 1210 CAMBRIDGE MA 02142
Business Address 101 MAIN STREET SUITE 1210 CAMBRIDGE MA 02142 617-949-2200
Clarus Lifesciences I, L.P. (Filed by) CIK: 0001431445 (see all company filings)

IRS No.: 203855540 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A

Mailing Address 94C INNOVATION DRIVE MILTON PARK ABINGDON X0 OX14 4RZ
Business Address 94C INNOVATION DRIVE MILTON PARK ABINGDON X0 OX14 4RZ 44 01235 442780
Oxford Immunotec Global PLC (Subject) CIK: 0001586049 (see all company filings)

IRS No.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-87926 | Film No.: 18596572
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
Office of Life Sciences